Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients1
暂无分享,去创建一个
D. Dunkler | G. Laufer | A. Zuckermann | E. Wolner | M. Ehrlich | N. Bonaros | M. Grimm | A. Kocher | J. Ankersmit
[1] D. Dunkler,et al. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[2] L. V. von Segesser,et al. Determinants of protracted cytomegalovirus infection in solid-organ transplant patients1 , 2002, Transplantation.
[3] S. Hunt,et al. IMPACT OF CYTOMEGALOVIRUS HYPERIMMUNE GLOBULIN ON OUTCOME AFTER CARDIOTHORACIC TRANSPLANTATION: A Comparative Study of Combined Prophylaxis with CMV Hyperimmune Globulin Plus Ganciclovir Versus Ganciclovir Alone , 2001, Transplantation.
[4] R. Rubin. Prevention and treatment of cytomegalovirus disease in heart transplant patients. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[5] T. Mohanakumar,et al. Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates , 2000, Clinical and experimental immunology.
[6] I. Sia,et al. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. , 2000, Clinical microbiology reviews.
[7] Vincent C. Emery,et al. The Dynamics of Human Cytomegalovirus Replication in Vivo , 1999, The Journal of experimental medicine.
[8] J. Gómez-Moreno,et al. Infection in organ-transplant recipients. , 1998, The New England journal of medicine.
[9] J. Griffith,et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. , 1997, Clinical transplantation.
[10] J. Wittes,et al. Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients. , 1996, Transplantation proceedings.
[11] J. Griffith,et al. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] H. Valantine. Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin. , 1995, Transplantation proceedings.
[13] G. Schreier,et al. Cytomegalovirus after heart transplantation: definitions for the guidance of antiviral therapy. , 1995, Scandinavian journal of infectious diseases. Supplementum.
[14] D. Latter,et al. Is the incidence of cytomegalovirus disease following heart transplantation decreased by prophylactic ganciclovir and CMV‐hyperimmunglobulin? , 1994, Transplant international : official journal of the European Society for Organ Transplantation.
[15] N. Liabakk,et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. , 1994, Blood.
[16] M. Leon,et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. , 1994, Science.
[17] S. Hammer,et al. Cytomegalovirus Immune Globulin Prophylaxis in Liver Transplantation , 1993, Annals of Internal Medicine.
[18] U. Andersson,et al. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. , 1993, Immunology.
[19] M. Nieminen,et al. Quantitation of cytomegalovirus infection-associated histologic findings in endomyocardial biopsies of heart allografts. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[20] Y. Masuho,et al. Neutralizing mechanisms of two human monoclonal antibodies against human cytomegalovirus glycoprotein 130/55. , 1992, The Journal of general virology.
[21] T. Merigan,et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. , 1992, The New England journal of medicine.
[22] S. Chou,et al. Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[23] M. Frank,et al. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. , 1992, Clinical immunology and immunopathology.
[24] M. Ho,et al. Epidemiology of cytomegalovirus infections. , 1990, Reviews of infectious diseases.
[25] R. Rubin,et al. Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice , 1989, Antimicrobial Agents and Chemotherapy.
[26] J. Jeekel,et al. Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection. , 1989, Transplantation.
[27] V. Starnes,et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. , 1989, JAMA.
[28] R. Rubin. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. , 1989, JAMA.
[29] T. Wreghitt. Cytomegalovirus infections in heart and heart-lung transplant recipients. , 1989, The Journal of antimicrobial chemotherapy.
[30] A. Levey,et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. , 1987, The New England journal of medicine.